Researchers analyzing UK Biobank cardiac imaging data identified papillary muscle hypertrophy as a promising new biomarker for Fabry disease, a rare genetic disorder that affects multiple organ systems. Their automated analysis confirmed maximum wall thickness remains diagnostically relevant, while introducing the PM/LV ratio—measuring papillary muscle area relative to left ventricular cavity—as having potential prognostic value. This finding matters because Fabry disease's non-specific symptoms often delay diagnosis by years, preventing timely enzyme replacement therapy that could prevent irreversible organ damage. Early cardiac involvement is common in Fabry disease, making improved imaging biomarkers particularly valuable for screening at-risk family members and monitoring disease progression. The automated pipeline approach also represents a scalable method for analyzing large imaging datasets. However, this preprint awaits peer review, and several limitations warrant caution. The UK Biobank's general population may contain few Fabry patients, potentially limiting statistical power. The study lacks validation in confirmed Fabry cohorts or comparison with current diagnostic standards like lyso-Gb3 levels. While promising for research applications, clinical implementation would require extensive validation studies comparing these imaging metrics against gold-standard genetic testing and clinical outcomes.